{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:37:23Z","timestamp":1784864243503,"version":"3.55.0"},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary plasma cell leukemia (<jats:styled-content style=\"fixed-case\">pPCL<\/jats:styled-content>) is the most aggressive form of the plasma cell (<jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>) malignancy, multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl\u20102 inhibitor, venetoclax, as a single agent in patients with relapsed <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl\u20102 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a <jats:styled-content style=\"fixed-case\">pPCL<\/jats:styled-content> patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl\u20102 inhibition\u2010based therapy as an option for therapy in patients with <jats:styled-content style=\"fixed-case\">pPCL<\/jats:styled-content> with t (11;14).<\/jats:p>","DOI":"10.1111\/ejh.12986","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T14:36:57Z","timestamp":1508855817000},"page":"215-217","source":"Crossref","is-referenced-by-count":59,"title":["Combination therapy incorporating Bcl\u20102 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson I.","family":"Gonsalves","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90942-9"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.336"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565051"},{"key":"e_1_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.4"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.184"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.488.488"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0730"},{"key":"e_1_2_2_9_1","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","author":"Moreau P","year":"2017","journal-title":"Blood"},{"key":"e_1_2_2_10_1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1182\/blood.V124.21.2053.2053","article-title":"Measurement of the proliferation of clonal plasma cells by multiparametric flow cytometry is a clinically useful tool in multiple myeloma","volume":"124","author":"Kochuparambil ST","year":"2014","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12986","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:24:10Z","timestamp":1695889450000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/ejh.12986"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12986","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]}}}